Fusion Antibodies plc

Default features description for sign up page.

Home

Board Profiles

Company Profile

Updates

Regulatory News

Company Presentations

Webinars

Share Price

New investors

Shareholder Information

Advisers

Company Information & FAQs

Corporate Governance

Fusion Deep Dive

Raleway

fab---interims-presentation-(19-11-24).pdf

CEO, Adrian Kinkaid, and Interim CFO, Stephen Smyth, present on the Company's interim results for the period ended 30 September 2024.

Highlighted throughout the presentation is Fusion Antibodies’ progress in revenue growth, the advancement of proprietary platforms like Mammalian Display and OptiPhage™, and strategic efforts to achieve cash flow break-even by H2 FY26. The presentation underlined the Company's reinforced commercial strategy and commitment to driving innovation in antibody discovery and development.

If you have any questions please submit them via the 'ask a question' button and our management team will get back to you as soon as they can.

Interim Results Presentation for the period ended 30 September 2024